Contemporary update on neoadjuvant therapy for bladder cancer.

Nguyen, Daniel Truong Phat; Thalmann, George (2017). Contemporary update on neoadjuvant therapy for bladder cancer. Nature Reviews. Urology, 14(6), pp. 348-358. Nature Publishing Group 10.1038/nrurol.2017.30

Full text not available from this repository. (Request a copy)

Administration of neoadjuvant chemotherapy preceding radical cystectomy in patients with bladder cancer remains a matter of debate. Results of prospective, randomized studies have demonstrated an overall absolute survival benefit of 5% at 5 years, provided cisplatin-based combination regimens are used. Owing to the perception of a modest survival benefit, the medical community has been slow to adopt the use of neoadjuvant chemotherapy. Other reasons for the underuse of neoadjuvant chemotherapy range from patient ineligibility to fear of delaying potentially curative surgery in nonresponders. Instead, several institutions have adopted an individualized, risk-adapted approach, in which the decision to administer chemotherapy is based on clinical stage and patient comorbidity profile. The development of new cytotoxic and targeted therapies, in particular immune checkpoint inhibitors, warrants well-designed prospective studies to test their efficacy alone or in combination in the neoadjuvant setting. Moving forward, genomic characterization of muscle-invasive bladder cancer could offer information that aids clinicians in selecting the appropriate chemotherapy regimen. Following neoadjuvant therapy, every effort should be made to ensure optimal surgery, as surgical margins and the number of removed lymph nodes are prognostic factors; thus, radical cystectomy and a meticulous extended pelvic lymph node dissection should be performed by expert surgeons.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Urology

UniBE Contributor:

Nguyen, Daniel Truong Phat, Thalmann, George

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1759-4820

Publisher:

Nature Publishing Group

Language:

English

Submitter:

Laetitia Hayoz

Date Deposited:

27 Feb 2018 12:33

Last Modified:

05 Dec 2022 15:09

Publisher DOI:

10.1038/nrurol.2017.30

PubMed ID:

28290459

URI:

https://boris.unibe.ch/id/eprint/108783

Actions (login required)

Edit item Edit item
Provide Feedback